Tenaya Therapeutics Reports Q1 Results, Announces Alnylam Collaboration Amidst Nasdaq Delisting Risk
TNYA has more than doubled off its 52-week low of $0.36.
Summary
Tenaya Therapeutics reported a reduced net loss in Q1 2026 and announced a significant collaboration with Alnylam Pharmaceuticals, but faces a Nasdaq delisting risk and high potential share dilution.
Key Events · Earnings and Guidance · TNYA
-
Q1 2026 Financial Performance
The company reported a net loss of $19.3 million for Q1 2026, a 28% improvement from the $26.9 million net loss in Q1 2025, driven by a 30% reduction in R&D expenses and a 16% reduction in G&A expenses.
-
New Collaboration with Alnylam Pharmaceuticals
In March 2026, Tenaya entered a multi-target research collaboration with Alnylam Pharmaceuticals to discover novel gene targets for cardiovascular disease. The agreement includes an upfront platform access fee of $10 million and potential development and commercial milestone payments of up to $1.1 billion.
-
Liquidity and Cash Runway
As of March 31, 2026, Tenaya had $80.9 million in cash and cash equivalents. Management believes existing cash will fund operations for at least the next twelve months from the filing date (into Q2 2027).
-
Nasdaq Delisting Notice
On January 28, 2026, the company received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price rule, with 180 calendar days to regain compliance.
Analysis · TNYA · Life Sciences
Tenaya Therapeutics' Q1 2026 results show a reduced net loss, primarily due to decreased operating expenses. The new collaboration with Alnylam Pharmaceuticals is a significant strategic development, offering substantial potential milestone payments and research funding, which could provide a long-term financial boost. However, the company faces immediate and critical challenges, including a Nasdaq delisting notice due to its stock price falling below $1.00, and a substantial overhang from potentially dilutive securities. The stated cash runway of at least 12 months is crucial for a clinical-stage biotech, highlighting the ongoing need for careful financial management and potential future capital raises.
At the time of this filing, TNYA was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.5M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.